demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
remdesivir DisCoVeRy ... SOLIDARITY ... NIH NIAID ACTT-1 Mahajan Norwegian NOR study ... Andreas ... GS-US-540-5774, 5 days GS-US-540-5773 ... GS-US-540-5774, 10 days CAP-China ...

2 studies excluded by filtering options 0

5209 SIMPLE (Grein), 0 2300excludednot a RCTrisk of bias not avaialble
5546 remdesevir external control, 0 0130selection pending